MRO Tracker · Pharma
When each protected medicine opens to Indian generics and biosimilars, and which Indian companies are already lined up. We list a molecule only when its Indian expiry date is confirmed in a court record or official filing.
Download this tracker as Excel
Ruxolitinib
- Status
- Opens 12 Dec 2026
- Indian patent
- IN 269841, in force until 12 December 2026
- Indian firms waiting
- Shilpa Medicare (restrained January 2026), Aurore Life Sciences (restrained July 2026) and Melody Healthcare (restrained 24 September 2026) were all stopped from selling before expiry
- Price control
- Not in NLEM 2022
- Approved uses
- Myelofibrosis, polycythaemia vera, graft versus host disease
Ibrutinib
- Status
- Opens end 2026
- Indian patent
- IN 262968. Court orders describe it as valid until 2026; the exact day is not stated in the orders we reviewed
- Indian firms waiting
- Natco, Hetero, BDR Pharma, Shilpa Medicare, Alkem and Laurus Labs restrained in December 2023; Emcure undertook in May 2025 not to sell until expiry
- Price control
- Not in NLEM 2022
- Approved uses
- Chronic lymphocytic leukaemia and other B cell blood cancers
Pembrolizumab
- Status
- Opens June 2028
- Indian patent
- Runs to June 2028
- Indian firms preparing
- CDSCO expert panels cleared or reviewed biosimilar trials by Enzene, Hetero, Intas and Sun Pharma (2025 to 2026), Shilpa Biologicals (protocol approved with changes, October 2026) and Zydus (ZRC 3323, changes asked, October 2026)
- Price control
- Not in NLEM 2022
- Approved uses
- Many cancers including lung, melanoma, head and neck
Dabrafenib
- Status
- Opens 4 May 2029
- Indian patent
- In force until 4 May 2029
- Indian firms waiting
- Zydus is bound by an August 2026 Delhi High Court decree not to launch before expiry; development work under the Bolar exemption is allowed
- Price control
- Not in NLEM 2022
- Approved uses
- BRAF V600 mutated melanoma and lung cancer, usually with trametinib
Netupitant + palonosetron
- Status
- Opens 18 Nov 2030
- Indian patent
- Composition and method patent granted 23 March 2023, valid until 18 November 2030
- Indian firms waiting
- Intas restrained in November 2026 after launching NO CINV; an earlier challenge by Zydus was dismissed
- Price control
- Not in NLEM 2022
- Approved uses
- Preventing nausea and vomiting from chemotherapy
Osimertinib
- Status
- Opens 2032
- Indian patent
- IN 297581, in force to 2032
- Indian firms waiting
- Post grant oppositions by Natco and Sunshine Organics failed; Westcoast Pharmaceutical Works is under a permanent injunction
- Price control
- Not in NLEM 2022
- Approved uses
- EGFR mutated non small cell lung cancer
Risdiplam
- Status
- Contested; patent to 11 May 2035
- Indian patent
- IN 334397, term to 11 May 2035
- Indian firms selling
- Natco, after the Delhi High Court refused Roche an interim injunction in March 2025 and Roche lost its appeals
- Price control
- Not in NLEM 2022
- Approved uses
- Spinal muscular atrophy
On watch: patent position contested, no confirmed expiry date
- Ribociclib (Novartis, Kisqali): a second Indian patent was granted in 2026 after a 15 year delay. Natco has asked the Delhi High Court to revoke it. In September 2026 the Kerala High Court held that the government may use Section 100 of the Patents Act to supply patented medicines.
- Vericiguat (Bayer): the Delhi High Court granted an interim injunction on Indian Patent 316570 in October 2026.
Already opened: 2019 to 2026
Molecules whose main Indian patent has expired or been revoked, with what happened next. Makers, prices and price control for these and 43 other molecules are in the Drug Market Entry Tracker.
| Molecule | Originator (brand) | Opened on | What happened |
|---|---|---|---|
| Nivolumab | Bristol Myers Squibb (Opdivo) | 2 May 2026 | Indian patent expired. The Supreme Court had dismissed a BMS petition on 11 February 2026. |
| Semaglutide | Novo Nordisk (Ozempic, Rybelsus, Wegovy) | 20 March 2026 | Product patent IN 262697 expired. Indian makers launched the next day. |
| Sacubitril + valsartan | Novartis (Vymada) | 12 September 2025 | Patent IN 414518 revoked. Natco, Torrent, MSN and Eris were cleared to sell. |
| Linagliptin | Boehringer Ingelheim (Trajenta) | August 2023 | Patent expired. About 63 brands followed. |
| Dapagliflozin (second patent) | AstraZeneca (Forxiga) | 15 May 2023 | Species patent IN 235625 expired. The Delhi High Court had refused an interim injunction. |
| Apixaban | Bristol Myers Squibb and Pfizer (Eliquis) | 17 September 2022 | Patent IN 247381 expired after suits against Cipla, Micro Labs, BDR and others. |
| Dapagliflozin | AstraZeneca (Forxiga) | 2 October 2020 | Patent IN 205147 expired. Zydus launched Dapaglyn on 4 October 2020. |
| Vildagliptin | Novartis (Galvus) | 9 December 2019 | Patent IN 212815 expired. Zydus launched Vinglyn at Rs 4.95, one sixth of the original price. |
Dates are taken from Delhi High Court orders and Patent Office records. A later patent on a form or formulation can still block launches after the main date. This is not legal advice.
One email a month. Reply to any email to unsubscribe. Privacy policy
Frequently asked questions
Which drug patent expires next in India?
Ruxolitinib, on 12 December 2026. Ibrutinib follows at the end of 2026.
When does pembrolizumab go off patent in India?
The Indian patent runs to June 2028. At least six Indian companies are in CDSCO biosimilar trials.
Can a generic launch before the patent date in India?
Only if the patent is revoked or a court refuses an injunction, as happened with risdiplam. Otherwise firms that launch early are restrained, as with ruxolitinib and ibrutinib.
Download this tracker as Excel
Every row on this page in one spreadsheet, ready to filter and share with your team. Free for internal use.
Your download is starting. Thank you.
We use your details only to share related MRO research. See our privacy policy.
Go deeper
- Ruxolitinib market entry brief (USD 750)
- CDSCO Decoded: monthly approvals and trial clearances, free
- India Biosimilars Market report
- India API Market report
Planning a launch on one of these dates?
We map the patent, the competing makers and the price fall to expect for your molecule.